These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17625780)

  • 61. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Lipid profile of atazanavir].
    Martínez Chamorro E
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():34-40. PubMed ID: 20116615
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era.
    MacArthur RD; DuPont HL
    Clin Infect Dis; 2012 Sep; 55(6):860-7. PubMed ID: 22700829
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.
    Ceccato MG; Bonolo PF; Souza Neto AI; Araújo FS; Freitas MI
    Braz J Med Biol Res; 2011 Nov; 44(11):1177-83. PubMed ID: 22052375
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Atazanavir-induced nephrolithiasis].
    Valencia ME; Moreno V
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
    [No Abstract]   [Full Text] [Related]  

  • 66. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.
    Pace CS; Martin AM; Hammond EL; Mamotte CD; Nolan DA; Mallal SA
    Antivir Ther; 2003 Aug; 8(4):323-31. PubMed ID: 14518702
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
    Estrela RC; Santoro AB; Barroso PF; Tuyama M; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Aug; 84(2):205-7. PubMed ID: 18288082
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inflammatory oedema of the legs: a new side-effect of lopinavir.
    Lascaux AS; Lesprit P; Bertocchi M; Levy Y
    AIDS; 2001 Apr; 15(6):819. PubMed ID: 11371707
    [No Abstract]   [Full Text] [Related]  

  • 71. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Darunavir in treatment-naïve patients. The ARTEMIS study].
    Estrada V; Fuster M
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():10-3. PubMed ID: 19195454
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dyslipidemia in HIV-infected individuals.
    Sprinz E; Lazzaretti RK; Kuhmmer R; Ribeiro JP
    Braz J Infect Dis; 2010; 14(6):575-88. PubMed ID: 21340298
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity?
    Murdoch IG; Jacobs TG; Nieuwenhuize RM; van Rossum-Schornagel QC; Schurink CAM; van Erp NP; Burger DM
    AIDS; 2022 Feb; 36(2):322-323. PubMed ID: 34934024
    [No Abstract]   [Full Text] [Related]  

  • 75. Antiretroviral therapy and the human immunodeficiency virus--improved survival but at what cost?
    Bradbury RA; Samaras K
    Diabetes Obes Metab; 2008 Jun; 10(6):441-50. PubMed ID: 17825081
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.
    Heath KV; Hogg RS; Singer J; Chan KJ; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):440-7. PubMed ID: 12138351
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART.
    Cahn P; Leite O; Rosales A; Cabello R; Alvarez CA; Seas C; Carcamo C; Cure-Bolt N; L'Italien GP; Mantilla P; Deibis L; Zala C; Suffert T
    Braz J Infect Dis; 2010; 14(2):158-66. PubMed ID: 20563442
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.
    Riddler SA; Li X; Otvos J; Post W; Palella F; Kingsley L; Visscher B; Jacobson LP; Sharrett AR;
    J Acquir Immune Defic Syndr; 2008 Jul; 48(3):281-8. PubMed ID: 18545156
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of dyslipidemia in patients with human immunodeficiency virus.
    Shalit P
    Rev Cardiovasc Med; 2014; 15 Suppl 1():S38-46. PubMed ID: 24987862
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Limitations of current HIV therapies: opportunities for improvement.
    Powderly WG
    J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S7-12; quiz S13, 15-6. PubMed ID: 12946061
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.